FDA declines to discuss Kalavritinos report

FDA declined to comment Thursday on a report that former lobbyist Jack Kalavritinos will take on a major role at the agency in the Trump administration. Kalavritinos is a member of the Trump transition team and was the director of government affairs at Covidien plc, which Medtronic plc (NYSE:MDT) acquired in 2015.

Multiple sources who did not wish to be identified told BioCentury that Kalavritinos would have a role at FDA, but did not specify a title. Kalavritinos did not respond to inquiries. ...